JP2012530120A5 - - Google Patents

Download PDF

Info

Publication number
JP2012530120A5
JP2012530120A5 JP2012515556A JP2012515556A JP2012530120A5 JP 2012530120 A5 JP2012530120 A5 JP 2012530120A5 JP 2012515556 A JP2012515556 A JP 2012515556A JP 2012515556 A JP2012515556 A JP 2012515556A JP 2012530120 A5 JP2012530120 A5 JP 2012530120A5
Authority
JP
Japan
Prior art keywords
sox11
activating
agent capable
diluent
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2012515556A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012530120A (ja
Filing date
Publication date
Priority claimed from GBGB0910620.4A external-priority patent/GB0910620D0/en
Application filed filed Critical
Publication of JP2012530120A publication Critical patent/JP2012530120A/ja
Publication of JP2012530120A5 publication Critical patent/JP2012530120A5/ja
Pending legal-status Critical Current

Links

JP2012515556A 2009-06-19 2010-06-18 薬剤およびその使用 Pending JP2012530120A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0910620.4A GB0910620D0 (en) 2009-06-19 2009-06-19 Agents and uses thereof
GB0910620.4 2009-06-19
PCT/GB2010/001200 WO2010146370A2 (en) 2009-06-19 2010-06-18 Agents and uses thereof

Publications (2)

Publication Number Publication Date
JP2012530120A JP2012530120A (ja) 2012-11-29
JP2012530120A5 true JP2012530120A5 (enExample) 2013-08-08

Family

ID=40972458

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012515556A Pending JP2012530120A (ja) 2009-06-19 2010-06-18 薬剤およびその使用

Country Status (6)

Country Link
US (1) US20120178698A1 (enExample)
EP (1) EP2442815A2 (enExample)
JP (1) JP2012530120A (enExample)
CA (1) CA2765770A1 (enExample)
GB (1) GB0910620D0 (enExample)
WO (1) WO2010146370A2 (enExample)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB9223084D0 (en) 1992-11-04 1992-12-16 Imp Cancer Res Tech Compounds to target cells
US20070237770A1 (en) * 2001-11-30 2007-10-11 Albert Lai Novel compositions and methods in cancer
SE0201863D0 (en) 2002-06-18 2002-06-18 Cepep Ab Cell penetrating peptides
WO2005002417A2 (en) * 2003-06-20 2005-01-13 Avalon Pharmaceuticals, Inc. Cancer -linked gene aas target for chemotherapy
US20050059682A1 (en) * 2003-09-12 2005-03-17 Supergen, Inc., A Delaware Corporation Compositions and methods for treatment of cancer
GB0709092D0 (en) * 2007-05-11 2007-06-20 Borrebaeck Carl Diagnosis and method of disease
GB0815846D0 (en) * 2008-09-01 2008-10-08 Immunovia Ab diagnosis, prognosis and imaging of disease
JP2010241711A (ja) * 2009-04-02 2010-10-28 Institute Of Physical & Chemical Research グリオーマの腫瘍形成に関わる遺伝子

Similar Documents

Publication Publication Date Title
IL274602A (en) Pharmaceutical tablets containing eltrombopag olamine, methods for their preparation and use thereof in the preparation of medicaments for treating thrombocytopenia
JP2014530220A5 (enExample)
IL223783B (en) Compound 1-converted indole for use in the treatment of a disease or condition, a pharmaceutical preparation containing the compound and use of the compound to prepare a medicine
BR112014014262A2 (pt) nanopartículas; composição farmacêutica; método de administrar um ou mais agentes terapêuticos, profiláticos, e/ou diagnósticos a um paciente em necessidade dos mesmos e método de preparação das partículas.
IL222120A (en) Annals (indole-1-yl) -carbonylalkyl, process for preparation, pharmaceutical preparations containing them and their use in the preparation of cancer drugs
JP2012255026A5 (enExample)
EA201401028A1 (ru) Фармацевтическая композиция, содержащая эмпаглифлозин и лекарственное средство от ожирения
JP2010529118A5 (enExample)
AR082091A1 (es) Composiciones farmaceuticas que comprenden pioglitazona y linagliptina y procedimiento de preparacion
JP2013155188A5 (enExample)
JP2013522184A5 (enExample)
IL216599A (en) 4,1-Bi-Conjugated Phthalazine History, Pharmaceuticals Containing Them and Their Use in Cancer Treatment
CL2016002132A1 (es) Uso de una cantidad de laquinimod, que sirve para preparar un medicamento para tratar un paciente humano afectado con esclerosis múltiple o que presenta un síndrome clínicamente aislado; un paquete, una cantidad de laquinimod y una composición farmacéutica del mismo.
BR112013011480A8 (pt) método de tratamento de câncer, método de aumento da eficácia terapêutica de uma droga anticâncer, pmo1183 ou um sal farmaceuticamente aceitável do mesmo, uso do mesmo e kit para uso no tratamento de câncer
HUE043540T2 (hu) Szubsztituált dimer kinazolin-származék, elõállítása, valamint alkalmazása 1-es és 2-es típusú cukorbetegség kezelésére szolgáló gyógyászati készítményekben
EP2753348A4 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF CANCER WITH AN INTERFERON ALPHA CONJUGATE
IL215826A (en) Pharmaceutical preparation with delayed release, process of preparation of the preparation, use of the preparation for the preparation of pain medication and the pill containing it.
WO2015160975A3 (en) Combination of a pi3k inhibitor with a bcl-2 inhibitor for use in the treatment of cancer
IL232325A0 (en) 18-methyl-7,6-methylene-3-oxo-17-paragan-4-en-21, 17b-carbolactones, pharmaceutical preparations containing these compounds and their use for the treatment of endometrial disease
MX366230B (es) Composiciones multipolimericas para liberación transdermica de farmaco.
IL232764A (en) Fluoromethyl6,5 - Dihydro - 4 H - [3,1] Oxazines, Pharmaceuticals Containing Them and Their Use in the Preparation of Medicines to Treat Alzheimer's Disease
EP2841107A4 (en) CYTOTOXIC ACTIVITIES DISPOSED OF HIV RELEASING MOLECULES (CDM-HS), CYTOTOXIC EFFECT AGAINST HUMAN IMMUNE WEAKAGE VIRUS AND METHOD OF USE
CL2013000677A1 (es) Composicion farmaceutica en forma de tabletas que comprenden microgranulos gastrointestinales que contienen 100 a 800 mg de rifaximina, hasta 30% p/p de excipientes extragranulares y un recubrimiento formador de pelicula; y uso para tratar una enfermedad infecciosa y/o inflamatoria del intestino, tal como la enfermedad de crohn.
HK1223304A1 (zh) 包含二甲双胍和二氢槲皮素的药物组合及其用於治疗癌症的用途
EP2509421A4 (en) ACTIVE COMPOSITION OF TEMOZOLOMIDE FOR SYSTEMIC CANCER TREATMENT